Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. Tsimberidou AM, et al. Cancer. 2010 Sep 1;116(17):4086-94. doi: 10.1002/cncr.25277. Cancer. 2010. PMID: 20564148 Free PMC article. Clinical Trial.
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.
Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2013 Feb;71(2):389-97. doi: 10.1007/s00280-012-2014-8. Epub 2012 Nov 11. Cancer Chemother Pharmacol. 2013. PMID: 23143207 Clinical Trial.
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2013 Apr;71(4):955-63. doi: 10.1007/s00280-013-2088-y. Epub 2013 Feb 3. Cancer Chemother Pharmacol. 2013. PMID: 23377373 Free PMC article. Clinical Trial.
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Hong DS, et al. Among authors: tsimberidou am. Lancet Oncol. 2014 May;15(6):656-66. doi: 10.1016/S1470-2045(14)70155-X. Epub 2014 Apr 17. Lancet Oncol. 2014. PMID: 24746841 Clinical Trial.
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Hong DS, et al. Among authors: tsimberidou am. Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17. Cancer. 2014. PMID: 24752867 Free article. Clinical Trial.
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Hong DS, et al. Among authors: tsimberidou am. Invest New Drugs. 2015 Jun;33(3):621-31. doi: 10.1007/s10637-015-0226-6. Epub 2015 Mar 31. Invest New Drugs. 2015. PMID: 25822109 Free PMC article. Clinical Trial.
287 results